It took 10 months following the release of final guidance, but the US FDA has finally attached a four-letter suffix to the non-proprietary name of a novel biologic with the agency's approval of Ultragenyx Pharmaceutical Inc.'s Mepsevii (vestronidase alfa-vjbk).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?